Name: Capital Market Publishers India Pvt. Ltd.
Telephone: 91-22-25229720

LOGIN HERE

Cancel

BSE Code : 531349 | NSE Symbol : PANACEABIO | ISIN : INE922B01023 | Industry : Pharmaceuticals - Indian - Bulk Drugs & Formln |

Board Meeting

Announcement Date	Date Of Meeting	Purpose	Detail
31-Jan-2025	14-Feb-2025	Quarterly Results	PANACEA BIOTEC LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/02/2025 inter alia to consider and approve Standalone and Consolidated Unaudited Financial Results (Provisional) for the quarter and nine months ended December 31 2024. The trading window of the Company shall remain closed for all Designated Persons till February 16 2025. Please find attached outcome of the Board Meeting of Panacea Biotec Limited held on February 14, 2025 (As Per Bse Announcement Dated on 14.02.2025)
30-Oct-2024	13-Nov-2024	Quarterly Results	PANACEA BIOTEC LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/11/2024 inter alia to consider and approve Standalone and Consolidated Unaudited Financial Results (Provisional) for the quarter and half year ended September 30 2024. With reference to our earlier announcement dated September 26 2024 intimating the Closure of Trading Window pursuant to the Companys Code of Conduct for Prevention of Insider Trading framed in accordance with SEBI (Prohibition of Insider Trading) Regulations 2015 as amended from time to time the trading window of the Company shall remain closed for all Designated Persons of the Company till November 15 2024. The Board of Directors of Panacea Biotec Limited has, at its meeting held today, 13.11.2024, inter-alia, considered and approved: 1. Unaudited Standalone and Consolidated Financial Results (Provisional) for the quarter and half year ended 30.09.2024; 2. Raising of funds by way of External Commercial Borrowings of an amount upto US$ 20 million (equivalent to ~Rs.168.16 Crore) from the U.S. International Development Finance Corporation; 3.Appointment of Mr. Rajesh Jain, Chartered Accountant as an additional director in the capacity of non-executive Independent Director, for a term of 5 years w.e.f. 13.11.2024, subject to the approval of the shareholders; and 4. Re-appointment of Dr. Rajesh Jain as Chairman and Managing Director, liable to retire by rotation, for a term of 3 years with effect from January 01, 2025, subject to the approval of the shareholders. (As Per BSE Announcement dated on 13.11.2024)
12-Nov-2024	12-Nov-2024	Quarterly Results	The Board of Directors of the Company''s unlisted material subsidiary, Panacea Biotec Pharma Ltd. has in its meeting held today i.e. 12.11.2024, inter-alia, approved the following: 1. Appointment of Mr. Rajesh Jain as an additional director in the capacity of independent director for a period of 5 years w.e.f. 12.11.2024, subject to approval of shareholders. 2. giving Corporate Guarantee in connection with proposed fund raising by the Company by way of External Commercial Borrowing of an amount upto US$ 20 million (equivalent to ~Rs.168.16 Crore) from the US International Development Finance Corporation in relation to expansion of manufacturing capacity of hexavalent vaccine and refinancing of its existing rupee loan availed by the Company from its affiliates. The details as required under SEBI LODR Regulations are enclosed herewith as Annexure - A and Annexure - B The Board of Directors of Panacea Biotec Limited has, at its meeting held today, 13.11.2024, inter-alia, considered and approved: 1. Unaudited Standalone and Consolidated Financial Results (Provisional) for the quarter and half year ended 30.09.2024; 2. Raising of funds by way of External Commercial Borrowings of an amount upto US$ 20 million (equivalent to ~Rs.168.16 Crore) from the U.S. International Development Finance Corporation; 3.Appointment of Mr. Rajesh Jain, Chartered Accountant as an additional director in the capacity of non-executive Independent Director, for a term of 5 years w.e.f. 13.11.2024, subject to the approval of the shareholders; and 4. Re-appointment of Dr. Rajesh Jain as Chairman and Managing Director, liable to retire by rotation, for a term of 3 years with effect from January 01, 2025, subject to the approval of the shareholders. (As Per BSE Announcement dated on 13.11.2024)
02-Aug-2024	14-Aug-2024	Quarterly Results	PANACEA BIOTEC LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/08/2024 inter alia to consider and approve the Standalone and Consolidated Unaudited Financial Results (Provisional) for the quarter ended June 30 2024. With reference to our earlier announcement dated June 27 2024 intimating the Closure of Trading Window pursuant to the Companys Code of Conduct for Prevention of Insider Trading framed in accordance with SEBI (Prohibition of Insider Trading) Regulations 2015 as amended from time to time the trading window of the Company shall remain closed for all Designated Persons of the Company till August 16 2024. Please find attached Outcome of Board Meeting held on August 14, 2024 (As Per BSE Announcement dated on 14.08.2024)
13-May-2024	30-May-2024	Accounts	PANACEA BIOTEC LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2024 inter alia to consider and approve the Audited Financial Results for the Quarter and Financial Year ended March 31 2024. With reference to our earlier announcement dated March 27 2024 intimating the Closure of Trading Window pursuant to the Companys Code of Conduct for Prevention of Insider Trading framed in accordance with SEBI (Prohibition of Insider Trading) Regulations 2015 as amended from time to time the trading window of the Company shall remain closed for all Designated Persons of the Company till June 01 2024. We would like to inform that pursuant to Regulations 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 , the Board of Directors of the Company has, at its meeting held today, i.e. May 30, 2024, inter-alia, considered and approved the Standalone and Consolidated Audited Financial Results of the Company for the Quarter and Financial Year ended March 31, 2024. The same was also reviewed by the Audit Committee in its meeting held on May 29, 2024. Read less.. (As Per BSE Announcement Dated on 30.05.2024) The Board in its meeting held on 30.05.2024 approved the re-designation of Mr. Ankesh Jain from Whole-time director designated as Director Sales & Marketing to Whole-time Director of the Company for the remaining tenure of his Term i.e. from 01.06.2024 to 31.03.2025. The Board of Directors of the Company''s wholly owned subsidiary company, Panacea Biotec Pharma Ltd. has also re-designated Mr. Ankesh Jain who is currently acting as its non-executive Director, to the position of Whole-time Director w.e.f. 01.06.2024. Mr. Ankesh Jain is not debarred from holding the office of Whole-time director in the Company as well as Panacea Biotec Pharma Ltd, by virtue of SEBI order or any other such authority (As Per BSE Announcement dated on 31.05.2024)
30-Jan-2024	13-Feb-2024	Quarterly Results	PANACEA BIOTEC LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/02/2024 inter alia to consider and approve the Standalone and Consolidated Unaudited Financial Results (Provisional) for the quarter and nine months ended December 31 2023. The trading window of the Company shall remain closed for all Designated Persons of the Company till February 15 2024 and the same will re-open from February 16 2024 1. Standalone and Consolidated Unaudited Financial Results (Provisional) along with Limited Review Report for the quarter and nine months ended December 31, 2023 2. Re-appointment of Mr. Bhupinder Singh as a Non-Executive Independent Director 3. Appointment of Mrs. Ambika Sharma as an additional director in the capacity of Non-Executive Independent Director (As per BSE Announcement Dated on 13/02/2024)
23-Oct-2023	10-Nov-2023	Quarterly Results	PANACEA BIOTEC LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/11/2023 inter alia to consider and approve the Standalone and Consolidated Unaudited Financial Results (Provisional) for the quarter and half year ended September 30 2023. The trading window of the Company shall remain closed for all Designated Persons of the Company till November 12 2023 We would like to inform you that the Board of Directors of the Company has, at its meeting held today, i.e. November 10, 2023, inter-alia, considered and approved the Unaudited Standalone and Consolidated Financial Results (Provisional) of the Company (which have been subjected to Limited Review by the Statutory Auditors) for the quarter and half year ended September 30, 2023. The same were also reviewed by the Audit Committee in its meeting held on November 09, 2023. A copy of the said statement of financial results along with the Limited Review Report is enclosed herewith. The meeting of the Board of Directors commenced at 11:30 A.M. and concluded at 01:25 P.M. (As Per BSE Announcement Dated on 10/11/2023)
29-Jul-2023	12-Aug-2023	Quarterly Results	PANACEA BIOTEC LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/08/2023 inter alia to consider and approve the Standalone and Consolidated Unaudited Financial Results (Provisional) for the quarter ended June 30 2023. PANACEA BIOTEC LIMITED has informed BSE about Board Meeting to be held on 12 Aug 2023 to consider financial statements for the period ended June 2023. Financial results / Other business. The Board considered and approved following matters:- (i) Unaudited Standalone and Consolidated Financial Results (Provisional) of the Company for quarter ended 30.06.2023; (ii) Revision in policy for determination of materiality of events and information and code of Conduct (iii) Date, time and venue of 39th Annual General Meeting - Friday, 29.09.2023 at 11:30 A.M (iv)Dates of Book Closure - 22.09.2023 to 29.09.2023 (As per BSE Announcement Dated on 12/08/2023)
15-May-2023	30-May-2023	Accounts	PANACEA BIOTEC LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2023 inter alia to consider and approve the Audited Financial Results for the Financial Year ended March 31 2023. Further with reference to our earlier announcement dated March 30 2023 intimating the Closure of Trading Window pursuant to the Companys Code of Conduct for Prevention of Insider Trading framed in accordance with SEBI (Prohibition of Insider Trading) Regulations 2015 as amended from time to time the trading window of the Company shall remain closed for all Designated Persons of the Company till June 01 2023 and the same will re-open from June 02 2023. The Board of Directors of the Company has, at its meeting held today, i.e. May 30, 2023, inter-alia, considered and approved the Standalone and Consolidated Audited Financial Results of the Company for the Quarter and Financial Year ended March 31, 2023. The same were also reviewed by the Audit Committee in its meeting held on May 29, 2023. The meeting of the Board of Directors commenced at 11:00 A.M. and concluded at 2:30 P.M. in view of operational losses, the Board of Directors has not recommended any dividend on the Preference as well as Equity Shares of the Company for the financial year ended March 31, 2023. (As Per BSE Announcement Dated on 30.05.2023)
01-Feb-2023	14-Feb-2023	Quarterly Results	Quarterly Results We would like to inform you that the Board of Directors of the Company has, at its meeting held today, i.e. February 14, 2023, inter-alia, considered and approved the Unaudited Standalone and Consolidated Financial Results (Provisional) of the Company (which have been subjected to Limited Review by the Statutory Auditors) for the quarter and nine months ended December 31, 2022. The same were also reviewed by the Audit Committee in its meeting held on February 13, 2023. A copy of the same along with the Limited Review Report is enclosed herewith as Annexure - A. The Board Meeting commenced at 10:30 A.M. and concluded at 1:15 P.M. We request you to kindly bring the above information to the notice of your members. (As per BSE Announcement Dated on 14/02/2023)
04-Nov-2022	14-Nov-2022	Quarterly Results	PANACEA BIOTEC LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/11/2022 inter alia to consider and approve Pursuant to Regulation 29 of the SEBI LODR Regulations this is to inform you that: (i) a meeting of the Board of Directors of the Company is scheduled to be held on Monday 14.11.2022 at New Delhi inter-alia to consider and approve the Standalone and Consolidated Unaudited Financial Results (Provisional) for the quarter and half year ended 30.09.2022. (ii) pursuant to Regulation 46(2) of the SEBI LODR Regulations notice of the said meeting is also being uploaded on the website of the Company. (iii) with reference to our earlier announcement dated 29.09.2022 intimating the Closure of Trading Window pursuant to the Companys Code of Conduct for Prevention of Insider Trading framed in accordance with SEBI (Prohibition of Insider Trading) Regulations 2015 as amended from time to time the trading window of the Company shall remain closed for all Designated Persons till 16.11.2022 and the same will re-open from 17.11.2022. This is for your kind information and record please. We would like to inform you that Board of Directors of the Company has, at its meeting held today, i.e. 14.11.2022, inter-alia, considered and approved the Unaudited Standalone and Consolidated Financial Results (Provisional) of the Company (which have been subjected to Limited Review by the Statutory Auditors) for the quarter and half year ended 30.09.2022. The same were also reviewed by the Audit Committee in its meeting held earlier on 14.11.2022. A copy of the same along with the Limited Review Report is enclosed herewith as Annexure - A. We wish to further inform you that the Board of Directors has also decided the elevation of Dr. Rajesh Jain, Managing Director to the position of Chairman & Managing Director of the Company. The meeting of the Board of Directors commenced at 02:30 P.M. and concluded at 4:40 P.M. We request you to kindly bring the above information to the notice of your members. We would like to inform you that Board of Directors of the Company has, at its meeting held today, i.e. 14.11.2022, inter-alia, considered and approved the Unaudited Standalone and Consolidated Financial Results (Provisional) of the Company (which have been subjected to Limited Review by the Statutory Auditors) for the quarter and half year ended 30.09.2022. The same were also reviewed by the Audit Committee in its meeting held earlier on 14.11.2022. A copy of the same along with the Limited Review Report is enclosed herewith as Annexure - A. We wish to further inform you that the Board of Directors has also decided the elevation of Dr. Rajesh Jain, Managing Director to the position of Chairman & Managing Director of the Company. The meeting of the Board of Directors commenced at 02:30 P.M. and concluded at 4:40 P.M. We request you to kindly bring the above information to the notice of your members. (As Per BSE Announcement Dated on 14.11.2022)
27-Jul-2022	09-Aug-2022	Quarterly Results	PANACEA BIOTEC LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/08/2022 inter alia to consider and approve the Standalone and Consolidated Unaudited Financial Results (Provisional) for the quarter ended June 30 2022. Further with reference to our earlier announcement dated June 28 2022 intimating the Closure of Trading Window pursuant to the Companys Code of Conduct for Prevention of Insider Trading framed in accordance with SEBI (Prohibition of Insider Trading) Regulations 2015 as amended from time to time we would like to inform that the trading window of the Company shall remain closed for all the Designated Persons of the Company and Material Subsidiary of the Company till August 11 2022 and the same will re-open from August 12 2022. The Board of Directors of the Company has, at its meeting held on 09.08.2022, inter-alia, considered and approved the Unaudited Standalone and Consolidated Financial Results (Provisional) for the quarter ended June 30, 2022. The same were also reviewed by the Audit Committee in its meeting held earlier on 09.08.2022. We wish to further inform you that the Board of Directors has also decided that: i) the 38th AGM of the Company will be held on Wednesday, 28.09.2022 at 11:30 A.M. through VC / Other Audio-Visual Means; and ii) the Register of Members and Share Transfer Books will remain closed from Wednesday, 21.09.2022 to Wednesday, 28.09.2022 (both days inclusive) for the purpose of AGM. The meeting of the Board of Directors commenced at 12:30 P.M. and concluded at 3:15 P.M. The Board of Directors of the Company has, at its meeting held today, i.e. August 09, 2022, inter-alia, considered and approved the Unaudited Standalone and Consolidated Financial Results (Provisional) of the Company (which have been subjected to Limited Review by the Statutory Auditors) for the quarter ended June 30, 2022. The same were also reviewed by the Audit Committee in its meeting held earlier on August 09, 2022. A copy of the same along with the Limited Review Report is enclosed herewith as Annexure - A. The meeting of the Board of Directors commenced at 12:30 P.M. and concluded at 3:15 P.M. (As Per BSE Announcement Dated on 09.08.2022)
09-May-2022	18-May-2022	Accounts	PANACEA BIOTEC LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 18/05/2022 inter alia to consider and approve the Standalone and Consolidated Audited Financial Results for the Quarter / Financial Year ended March 31 2022. Further pursuant to Regulation 46(2) of the SEBI LODR Regulations notice of the said meeting is also being uploaded on the website of the Company. Further with reference to our earlier announcement dated March 31 2022 intimating the Closure of Trading Window pursuant to the Companys Code of Conduct for Prevention of Insider Trading framed in accordance with SEBI (Prohibition of Insider Trading) Regulations 2015 as amended from time to time we would like to inform that the trading window of the Company shall remain closed for all Designated Persons of the Company and Material Subsidiaries of the Company till 48 hours after the declaration of the financial results by the Company i.e. till May 20 2022. We would like to inform you that the Board of Directors of the Company has, at its meeting held today, i.e. May 18, 2022, inter-alia, considered and approved the following:- a. Standalone and Consolidated Audited Financial Results of the Company for the Quarter and Financial Year ended March 31, 2022. The same were also reviewed by the Audit Committee in its meeting held earlier on May 18, 2022. A copy of the same along with the Auditors' Report is enclosed herewith as Annexure - A. b. Seeking shareholders approval through Postal Ballot for : Appointment of Mr. Narotam Kumar Juneja (DIN: 01204817) as a Non-Executive Non-Independent Director; Adoption of new set of Articles of Association of Company; and Granting of loans, guarantees etc. and investment by way of acquisition of securities of any other bodies corporate & mutual funds etc. The meeting of the Board of Directors commenced at 12:30 P.M. and concluded at 2:40 P.M. (As Per BSE Announcement dated on 18.05.2022)
03-Feb-2022	14-Feb-2022	Quarterly Results	PANACEA BIOTEC LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/02/2022 inter alia to consider and approve the Standalone and Consolidated Unaudited Financial Results (Provisional) for the quarter and nine months ended December 31 2021. Further pursuant to Regulation 46(2) of the SEBI LODR Regulations notice of the said meeting is also being uploaded on the website of the Company. Further with reference to our earlier announcement dated December 31 2021 intimating the Closure of Trading Window pursuant to the Companys Code of Conduct for Prevention of Insider Trading framed in accordance with SEBI (Prohibition of Insider Trading) Regulations 2015 as amended from time to time we would like to inform that the trading window of the Company shall remain closed for all Designated Persons of the Company till February 16 2022 and the same will re-open from February 17 2022. We would like to inform you that the Board of Directors of the Company has, at its meeting held today, i.e. February 14, 2022, inter-alia, considered and approved the Unaudited Standalone and Consolidated Financial Results (Provisional) of the Company (which have been subjected to Limited Review by the Statutory Auditors) for the quarter and nine months ended December 31, 2021. Pursuant to Regulation 47(1)(b) of SEBI LODR Regulations, the Extract of Statement of above said financial results for the quarter and nine months ended December 31, 2021 in the Format as prescribed in Annexure I of SEBI Circular No. CIR/CFD/FAC/62/2016 dated 05.07.2016 is being sent for publication in newspapers. The meeting of the Board of Directors commenced at 02:30 P.M. and concluded at 04:00 P.M. We request you to kindly bring the above information to the notice of your members. (As Per BSE Announcement Dated 14.02.2022)
25-Jan-2022	01-Feb-2022	Raising funds through Debt Instr.	PANACEA BIOTEC LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 01/02/2022 inter alia to consider and approve the proposal of raising funds in such manner and on such terms as may be decided by the Board of Directors of the Company and / or its subsidiary company subject to such regulatory /statutory approvals as may be required. The Board would also consider convening Extra-ordinary General Meeting of its shareholders for seeking their approval in accordance with the relevant provisions of the Act. Further the trading window of the Company is already closed for all Designated Persons of the Company from January 01 2022 and shall continue to remain closed till completion of 48 hours from the announcement to the Stock Exchanges regarding Unaudited financial results of the Company for the quarter and nine months ended December 31 2021. We would like to inform that the Board of Directors in its meeting held on 01.02.200 had: taken on record the resolution passed by the Company's wholly-owned subsidiary for sale, transfer or disposal of its domestic business assets constituting its pharmaceutical formulations brands in India and Nepal including related trademarks, copyrights and such other intellectual property as may be agreed, inventories, etc. to Mankind Pharma Limited ('Buyer') and/or subsidiaries of Buyer; and approved the said Transaction. In the said meeting, the Board had also convened an Extra-ordinary General Meeting of the Company on Saturday, February 26, 2022 at 11.30 AM through Video Conferencing / Other Audio-Visual Means. The meeting of the Board of Directors commenced at 11:30 A.M. and concluded at 12:15 P.M. (As Per BSE Announcement dated on 01.02.2022)

1 2

LOGIN HERE

Panacea Biotec Ltd

Board Meeting